Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20053649 | 0.64 | — | — | |
| SCHEMBL27501095 | 0.64 | — | — | |
| SCHEMBL18676797 | 0.63 | — | — | |
| SCHEMBL12670846 | 0.62 | SLC6A2 (0.34) | — | |
| SCHEMBL13098099 | 0.61 | — | — | |
| SCHEMBL8372293 | 0.61 | MRGPRX2 (0.32) | — | |
| SCHEMBL17850651 | 0.60 | — | — | |
| SCHEMBL21400026 | 0.60 | — | — | |
| SCHEMBL8191246 | 0.60 | — | — | |
| SCHEMBL27446125 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162198-A1 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-26 | — | — | US | disclosed |
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-08-05 | — | — | US | disclosed |
| US-10724099-B2 | Multiplex methods to assay mixed cell populations simultaneously | THE BROAD INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20170088872-A1 | COMPOSITIONS AND METHODS FOR PRODUCING PODOPHYLLOTOXIN DERIVATIVES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-03-30 | — | — | US | disclosed |
| EP-2338889-B1 | Diazacyclic compounds having affinity for opioid receptors | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-08-29 | — | — | EP | disclosed |
| WO-2008067644-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2004065382-A1 | DIAZEPANES DERIVATIVES USEFUL AS LFA INHIBITORS | NOVARTIS AG (CH) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | KDM1A, KDM4A, KDM1B | DYRK1A 957/4885 |
| US-20220162198-A1 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM | CPT1B, GYS1, PYGM | DYRK1A 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.